Safety of Intravenous Lidocaine Infusions

N/ACompletedNCT01091935

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's70 enrolled

Overview

The purpose of this study is to prospectively determine the side effects profile in adults with neuropathic pain receiving intravenous infusions of lidocaine 5 mg per kg of lean body weight, infused over 45 minutes.

Eligibility Criteria: Adults \> 18 yrs with chronic central or peripheral neuropathic pain at the St Joseph's Health Care Pain Clinic between June and December 2009. Outcome measures: All side effects spontaneously reported. Sedation, nausea, dizziness by Visual Analog Score Q 15 minutes; hemodynamic data q 5 minutes during and after infusion for 30 minutes. Daily diary of side effects and Visual Analogue score of Pain for 7 days post-infusion.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Neuropathic Pain

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult outpatients \> 18 years \< 80 years diagnosed with chronic neuropathic pain Exclusion Criteria: * Unable to provide informed consent * Unable to speak and understand English * Liver, kidney, or cardiac failure * Allergy to Lidocaine

Locations (1)

St Joseph's Health Care

London, Ontario, Canada

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.